Table 2

Disease activity in patients with primary Sjögren's syndrome treated with rituximab

OutcomeBaselineWeek 16p Value*Week 24p Value*Week 36p Value*Week 48p Value*Week 60p Value*
ESSPRI6.3±2.2 (6.7)4.6±2.0 (5.3)0.0005.3±2.0 (5.3)0.0015.3±2.0 (5.3)0.0075.8±1.9 (6.3)0.0685.6±2.2 (5.7)0.043
ESSDAI8±5 (8)3±3 (2)0.0003±3 (2)0.0003±3 (2)0.0005±7 (4)0.0648±6 (5)0.662
Patient's GDA58±22 (60)31±25 (26)0.00038±24 (37)0.00030±21 (25)0.00035±22 (32)0.00043±25 (46)0.010
Physician's GDA53±16 (55)15±9 (11)0.00010±7 (10)0.00014±11 (10)0.00024±15 (20)0.00036±20 (40)0.000
IgM-Rf143±164 (90)65±75 (41)0.00065±79 (38)0.00096±150 (41)0.000130±195 (59)0.275159±251 (66)0.587
SWS0.42±0.37 (0.31)0.46±0.48 (0.29)0.2720.49±0.47 (0.32)0.2560.45±0.49 (0.27)0.6920.46±0.48 (0.23)0.4280.40±0.48 (0.22)0.762
  • Values presented as mean±SD (median).

  • * p value compared with baseline.

  • ESSDAI, EULAR Sjögren's Syndrome Disease Activity Index; ESSPRI, EULAR Sjögren's Syndrome Patients Reported Index; GDA, global disease activity assessment; IgM-Rf, rheumatoid factor; SWS, stimulated whole salivary flow.